Orizuru Therapeutics, Inc.
R&D-driven company developing iPSCs to cure life-threatening diseases with large unmet needs.
R&D-driven company developing iPSCs to cure life-threatening diseases with large unmet needs.
Orizuru Therapeutics, Inc. is a promising R&D-driven startup with the noble goal of using induced pluripotent stem cell (iPSC) technology to develop groundbreaking regenerative medicine. Founded in 2021 as a spinout from Takeda Pharmaceuticals and Kyoto University, the company is dedicated to finding cures for life-threatening diseases with significant unmet needs. Operating in the Biotechnology and Pharmaceutical industries, Orizuru Therapeutics, Inc. holds immense potential in addressing critical medical challenges. As of now, specific headquarters location and investment details remain undisclosed, but the company's mission and roots in established institutions make it a compelling entity to watch in the biotech startup space.
There is no investment information
No recent news or press coverage available for Orizuru Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.